
What is claimed is:

1. A compound of Chemical Formula 1 below or a salt thereof:


[Chemical Formula 1]



wherein, R_1 is hydrogen; alkyl of 1 to 10 carbon atoms; or substituted or unsubstituted alkylcarbonyl of 1 to 5 carbon atoms, and R_2 is alkyl of 6 to 9 carbon atoms.

2. A pharmaceutical composition for use in preventing or treating a neurodegenerative disease or depression, wherein the pharmaceutical composition comprises a compound of Chemical Formula 1 below, or a pharmaceutically acceptable salt thereof, as an active ingredient:

[Chemical Formula 1]



wherein, R_1 is hydrogen; alkyl of 1 to 10 carbon atoms; or substituted or unsubstituted alkylcarbonyl of 1 to 5 carbon atoms, and R_2 is alkyl of 6 to 9 carbon atoms.

3. ~~Use of the~~ The pharmaceutical composition ~~of~~ for use according to claim 2,

wherein the compound of Chemical Formula 1 is 2-amino-2-(1-hexyl-1H-1,2,3-triazol-4-yl)propane-1,3-diol, 2-amino-2-(1-heptyl-1H-1,2,3-triazol-4-yl)propane-1,3-diol, 2-amino-2-(1-octyl-1H-1,2,3-triazol-4-yl)propane-1,3-diol, or 2-amino-2-(1-nonyl-1H-1,2,3-triazol-4-yl)propane-1,3-diol.


4. ~~Use of the~~ The pharmaceutical composition ~~of~~ for use according to claim 2, wherein the neurodegenerative disease is at least one selected from the group consisting of Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, multiple system atrophy, olivopontocerebellar atrophy (OPCA), Shire-Dragger syndrome, striatum-nigral degeneration, Huntington's disease, amyotrophic lateral sclerosis (ALS), essential tremor, corticobasal degeneration, diffuse Lewy body disease, Parkin's-ALS-dementia complex, pick disease, cerebral ischemia, and cerebral infarction.

5. ~~Use of the~~ The pharmaceutical composition ~~of~~ for use according to claim 2, wherein the composition is to be administered orally.

6. ~~Use of the~~ The pharmaceutical composition ~~of~~ for use according to claim 2, wherein the pharmaceutical composition is a food composition.

7. A composition for use in *in vivo* diagnosing a neurodegenerative disease or depression, wherein the composition comprises a compound of Chemical Formula 1 below, or a pharmaceutically acceptable salt thereof, to which a diagnostic agent or detection agent is bound, as an active ingredient:


[Chemical Formula 1]



wherein, R_1 is hydrogen; alkyl of 1 to 10 carbon atoms; or substituted or unsubstituted alkylcarbonyl of 1 to 5 carbon atoms, R_2 is alkyl of 6 to 9 carbon atoms and the defined alkyl alkylcarbonyl each contains or does not contain a radioactive isotope.

8. Use of a compound of Chemical Formula 1 below, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for preventing or treating a neurodegenerative disease or depression:


[Chemical Formula 1]



wherein, R_1 is hydrogen; alkyl of 1 to 10 carbon atoms; or substituted or unsubstituted alkylcarbonyl of 1 to 5 carbon atoms, and R_2 is alkyl of 6 to 9 carbon atoms.

9. Use of a compound of Chemical Formula 1 below, or a pharmaceutically acceptable salt thereof to which a diagnostic agent or detection agent is bound, in the manufacture of a medicament for diagnosing a neurodegenerative disease or depression:

[Chemical Formula 1]



wherein, R_1 is hydrogen; alkyl of 1 to 10 carbon atoms; or substituted or unsubstituted alkylcarbonyl of 1 to 5 carbon atoms, R_2 is alkyl of 6 to 9 carbon atoms, and the defined alkyl or alkylcarbonyl each contains or does not contain radioactive isotopes.